Adult Precursor T-Lymphoblastic Leukemia/Lymphoma with Myeloid-Associated Antigen Expression Is Associated with a Lower Complete Remission Rate following Induction Chemotherapy

Acta Haematologica

Volumn 120, Issue 1, 2008, Pages 5-10

  Al Khabori, Murtadha ^a   Samiee, Samira ^a   Fung, Sharon ^a   Xu, Wei ^a   Brandwein, Joseph ^a   Patterson, Bruce ^a   Brien, William ^a   Chang, Hong ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Adult T lymphoblastic leukemia lymphoma; Cytogenetics; Immunophenotype; Lymphoblastic leukemia lymphoma, prognosis; Myeloid associated antigens

Indexed keywords

ANTIGEN; ANTINEOPLASTIC AGENT; ASPARAGINASE; CD34 ANTIBODY; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; MYELOID ASSOCIATED ANTIGEN; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENDER; HUMAN; KARYOTYPE; LEUKOCYTE; LYMPHATIC LEUKEMIA; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; RISK; T LYMPHOBLAST; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD13; ANTIGENS, CD34; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MIDDLE AGED; NEPRILYSIN; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE;

EID: 54249162407     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000146081     Document Type: Article

References (28)

1. Boissel N, Auclerc M-F, Lheritier V, Perel Y, Thomas X, Leblanc T, Rousselot P, Cayuela J-M, Gabert J, Fegueux N, Piguet C, Huguet-Rigal F, Berthou C, Boiron J-M, Pautas C, Michel G, Fiere D, Leverger G, Dombret H, Baruchel A: Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003;21:774-780.
2. Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ, Schulman P, Davey FR, Frankel SR, Bloomfield CD, George SL, Schiffer CA: A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998;92:1556-1564.
3. Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S, Kuriyama K, Ohtake S, Yagasaki F, Murakami H, Asou N, Ino T, Okamoto T, Usui N, Nishimura M, Shinagawa K, Fukushima T, Taguchi H, Morii T, Mizuta S, Akiyama H, Nakamura Y, Ohshima T, Ohno R: Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002;16:1259-1266.
4. Sobol RE, Mick R, Royston I, Davey FR, Ellison RR, Newman R, Cuttner J, Griffin JD, Collins H, Nelson DA, Bloomfield CD: Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med 1987;316:1111-1117.
5. Yanada M, Jinnai I, Takeuchi J, Ueda T, Miyawaki S, Tsuzuki M, Hatta Y, Usui N, Wada H, Morii T, Matsuda M, Kiyoi H, Okada M, Honda S, Miyazaki Y, Ohno R, Naoe T: Clinical features and outcome of T-lineage acute lymphoblastic leukemia in adults: a low initial white blood cell count, as well as a high count predict decreased survival rates. Leuk Res 2007;31:907-914.
6. Vitale A, Guarini A, Ariola C, Mancini M, Mecucci C, Cuneo A, Pane F, Saglio G, Cimino G, Tafuri A, Meloni G, Fabbiano F, Recchia A, Kropp MG, Krampera M, Cascavilla N, Ferrara F, Romano A, Mazza P, Fozza C, Paoloni F, Vignetti M, Foa R: Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood 2006;107:473-479.
7. Gökbuget N, Arnold R, Buechner Th: Intensification of induction and consolidation improves only subgroups of adult ALL: analysis of 1200 patients in GMALL study 05/93 (abstract). Blood 2001;98:802a.
8. Asnafi V, Buzyn A, Thomas X, Huguet F, Vey N, Boiron JM, Reman O, Cayuela JM, Lheritier V, Vernant JP, Fiere D, Macintyre E, Dombret H: Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. Blood 2005;105:3072-3078.
9. Storring JM, Brandwein J, Gupta V, Schuh AC, Schimmer A, Yee K, Wells RA, Lipton JH, Messner HA, Xu W, Minden MD: Treatment of adult acute lymphoblastic leukemia (ALL) with a modified DFCI pediatric regimen - the Princess Margaret experience (abstract). Blood 2006;108:1875.
10. Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, Hagemeister FB, Cabanillas FF, Murphy S, Keating MJ, Kantarjian H: Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999;17:2461-2470.
11. Stewart K, Keating A, Sutton D, Scott JG, Francombe W, Carter WH, Baker MA: Adult acute lymphoblastic leukaemia: the value of therapy intensification. Leuk Lymphoma 1991;4:103-110.
12. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, Lazarus HM, Franklin IM, Litzow MR, Ciobanu N, Prentice HG, Durrant J, Tallman MS, Goldstone AH, ECOG;MRC/NCRI Adult Leukemia Working Party: Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005;106:3760-3767.
13. Chang H, Salma F, Yi QL, Patterson B, Brien B, Minden MD: Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res 2004;28:43-48.
14. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van't Veer MB: Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9:1783-1786.
15. Hoelzer D, Gokbuget N, Digel W, Faak T, Kneba M, Reutzel R, Romejko-Jarosinska J, Zwolinski J, Walewski J: Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002;99:4379-4385.
16. Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, Ferrara F, Peta A, Ciolli S, Deplano W, Fabbiano F, Sica S, Di Raimondo F, Cascavilla N, Tabilio A, Leoni P, Invernizzi R, Baccarani M, Rotoli B, Amadori S, Mandelli F: Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002;99:863-871.
17. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-178.
18. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ: Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004;101:2788-2801.
19. Thiebaut A, Vernant JP, Degos L, Huguet FR, Reiffers J, Sebban C, Lepage E, Thomas X, Fiere D: Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 2000;14:1353-1366.
20. Pullen J, Shuster JJ, Link M, Borowitz M, Amylon M, Carroll AJ, Land V, Look AT, McIntyre B, Camitta B: Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study. Leukemia 1999;13:1696-1707.
21. Drexler HG, Thiel E, Ludwig WD: Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. Leukemia 1991;5:637-645.
22. Wiersma SR, Ortega J, Sobel E, Weinberg KI: Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. N Engl J Med 1991;324:800-808.
23. Boldt DH, Kopecky KJ, Head D, Gehly G, Radich JP, Appelbaum FR: Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience. Leukemia 1994;8:2118-2126.
24. Uckun FM, Sather HN, Gaynon PS, Arthur DC, Trigg ME, Tubergen DG, Nachman J, Steinherz PG, Sensel MG, Reaman GH: Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 1997;90:28-35.
25. Boucheix C, David B, Sebban C, Racadot E, Bene MC, Bernard A, Campos L, Jouault H, Sigaux F, Lepage E, Herve P, Fiere D: Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Blood 1994;84:1603-1612.
26. Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J, Qumsiyeh M, Moore JO, Mayer RJ, Davey F, Schiffer CA, Bloomfield CD: Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999;17:3767-3775.
27. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW, Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute: Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007;109:3189-3197.
28. Rambaldi A, Attuati V, Bassan R, Neonato MG, Viero P, Battista R, Di Bona E, Rossi G, Pogliani E, Ruggeri M, Amaru R, Rivolta A, Giudici G, Biondi A, Barbui T: Molecular diagnosis and clinical relevance of t(9;22), t(4; 11) and t(1;19) chromosome abnormalities in a consecutive group of 141 adult patients with acute lymphoblastic leukemia. Leuk Lymphoma 1996;21:457-466.